Biomarkers are an emerging area of focus in neurodegenerative diseases. This new scrutiny has arisen because biomarkers may provide an important link between preclinical disease models and the evaluation of disease progression in patients. One of these biomarkers, neurofilament light chain (NF-L), a neuronal cytoplasmic protein, is increased in a variety of neuronal diseases due …
QPS Neuropharmacology Announces Cooperation with the University of Bari Aldo Moro for Autism Spectrum Disorder R&D Project
QPS Neuropharmacology and the research group of Marcello Leopoldo from the University of Bari Aldo Moro, Italy, are collaborating on a funded research project related to autism spectrum disorder (ASD). Funding by the Austrian Research Promotion Agency (FFG) to perform the whole study within the frame of the industry-related PhD program (“Industrienahe Dissertation”) has been …
How and Why In Vitro Testing Is a Benefit to Neuropharmacology
Preclinical trials and studies of all kinds involve a number of different types of testing, including in vivo, in situ, in silico, and in vitro testing. Briefly, in vivo testing is performed in or on a whole living organism (usually an animal), in situ testing occurs where the organism is found in nature, while in …
Exploring CAA as an Independent Risk Factor for Cognitive Dysfunction or Alzheimer’s Disease
Are you looking to explore Cerebral Amyloid Angiopathy (CAA) as an independent risk factor for cognitive dysfunction or Alzheimer’s disease? QPS Austria, one of the top preclinical and clinical CROs in Europe, is ready to partner with you to provide visualization and quantification of CAA in murine tissues. In the last five years, there has …
